Johnson & Johnson Q1 Beats on EPS, Oncology Drives Growth
Johnson & Johnson reported Q1 revenue of $24.06B and adjusted EPS of $2.70, beating consensus for the fourth straight quarter, driven by strong oncology drug sales.
Johnson & Johnson (JNJ) reported first-quarter revenue of $24.06 billion, up 9.9% year over year, with adjusted earnings per share of $2.70 beating consensus estimates for the fourth consecutive quarter. The strong performance was driven by the company's oncology portfolio, with CARVYKIT up 62.1% to $597 million and RYBREVANT surging 82.7%, offsetting a 59.7% decline in STELARA due to biosimilar competition.
The results underscore the resilience of J&J's pharmaceutical segment amid patent losses and highlight the growing contribution of its cancer drugs. For traders, the consistent earnings beats and robust oncology pipeline provide a buffer against headwinds from legacy drug erosion. The company's planned separation of its Orthopaedics business is expected to further streamline operations and support margin expansion. Live commodities prices and charts on NowPrice show how the market is reacting to the earnings release and sector trends.
Looking ahead, investors will focus on the progress of the Orthopaedics separation and the continued uptake of CARVYKIT and RYBREVANT. The company's 90% confidence buy rating with a $252.01 price target implies a 9.37% upside from current levels. Key catalysts include regulatory updates on new drug approvals and the pace of biosimilar competition for STELARA. The next earnings report will provide further clarity on the trajectory of J&J's transformation.